



EUROPEAN COMMISSION  
DIRECTORATE-GENERAL  
Joint Research Centre



Joint Research Centre

# ECVAM efforts in nano- and biotechnology

Thomas Hartung & ECVAM Team

*Institute for Health and Consumer Protection (IHCP)  
Ispra (Va), Italy*

<http://ecvam.jrc.it>

*ihcp*



# Biologicals

- Meeting with EDQM and WHO March 2005:  
Identify methods to replace intracerebral challenge in Kendrick test  
(potency testing of whole-cell pertussis vaccines)  
  
➡ Start of 2 ECVAM studies to optimise serological tests
- Start of pyrogenicity peer review process end of June 2005
- ECVAM/DG SANCO workshop on 3Rs Approaches in Marine Biotoxin Testing – draft report in consultation with experts
- Scientific advice to CRL (Vigo) on prevalidation of functional assay for PSP testing
- Botulinum toxin: ECVAM in contact with EDQM regarding meeting with manufacturers, workshop with ICCVAM planned
- Comments on Ph.Eur. Monographs published in Pharmeuropa



## ***Biologicals as door-openers for a new safety toxicology for pharmaceuticals?***

- **Today 50% of new drugs are biologicals (e.g. recombinant proteins, antibodies)**
- **Classical safety toxicology is useless**
- **Biologicals have failed because of side-effects in studies and clinical use**
- **A predictive toxicology e.g. based on human cells is urgently required**



## ECVAM Research activities



### Coaching and steering of DG RTD projects

- IP ReProTect started 7'04
- IP A-Cute-Tox started 1'05
- IP Sens-it-iv start 10'05
- STREP Predictomics started 9'04
- STREP ToxDrops started 1'05
- STREP Vitrocellomics start 11'05
- Marie-Curie PulmoNet started 4'05

Impact: Total funding > 40 million Euro, > 120 partner institutions

### Own research

- Link to other units (ECB, PCE, BMS, GMO)
- Ecotoxicology test strategy (with ECB) validated 9'05  
(potential of saving 60% of fish for acute ecotox.)
- Cancer assay now under validation
- 8 Ph.D. (Adler, Boveri, Dodevich, Gartlon, Hoffmann Kinsner, Pellizzer, Malerba)
- About 50 original publications per year including Nature and PNAS, reports/reviews/citations in Nature, Science, Scientific American


thcp



## Why is Nano Different?

At the micron and larger scale, classical physics determines properties.

- At the Angstrom (0.1 nm) scale, quantum mechanics determines properties.
- At the nanometer scale, fundamental properties depend on exactly how big the particle is.



Slide by K. Ausman

From K.M.Kulinowski, Nanotechnology "The Big Science of the Very Small",  
CBEN

## *Type of exposure to metallic nanoparticles*

### **Environmental**

- Emission from automotive catalytic converters ( $\text{Pt}^0$  on  $\text{Al}_2\text{O}_3$ ,  $\text{CeO}_2$  on Co)
- Cosmetic (sunscreen,  $\text{TiO}_2$  ultrafine), ceramic, textile, semiconductor industries ( $\text{CeO}_2$ , ZnO,  $\text{SiO}_2$ , Ag on  $\text{TiO}_2$ ,  $\text{ZrO}_2$ , Ag, Au, Pt)....

### **Occupational**

- Large scale preparation of nanoparticles (tons of carbon nanotubes,  $\text{Co}_3\text{O}_4/\text{Fe}_2\text{O}_3$ )....

### **Biomedical**

- Tumor diagnosis and therapy (ultrafine  $\text{TiO}_2$  as killing compound of cancer cells by UV light), quantum dots (CdSe), supermagnetic Fe for diagnosis, Ag in catheters (antimicrobial action)





## Towards a European Strategy for Nanotechnology

On the 7th June 2005, the European Commission adopted the Action Plan  
**"Nanosciences and nanotechnologies: An action plan for Europe 2005-2009"**  
(COM(2005) 243) ...

How to ensure that nanotechnology is safe?

- Applications of nanotechnology must ensure a high level of public health, safety, consumer and environmental protection.
- Any risks must be addressed upfront and as an integral part of the R&D process.
- Specific toxicological studies for e.g. nanoparticles are underway at EU and national level.





## ***In Vitro* nanotoxicology research on manufactured nanoparticles**

### **Since 2003**

- Starting of the *In vitro* NAno TOXicology (INATOX) project (development of multidisciplinary methodology to understand the “nanosafety” and interaction of NP with cells, subcellular structures and biomolecules (ECVAM/BMS Units))
- 6 Contributions, support to DGs (RTD, Sanco)
- 8 International Conferences/Workshops, 5 Invited Seminars at Universities
- Partnership of Integrated (NANOIMPACT, INTELTEX) and STREP (Cellnanotox, DIPNA) projects
- Workshop on Health Effects on Nanoparticles (first part of 2006)





## *In vitro nanoparticles mechanistically-based toxicology research at the JRC*

**Cellular models used at ECVAM Unit**

**Exposure to manufactured nanoparticles**

**Toxicokinetics  
(uptake, intracellular  
distribution,  
biotransformation,  
binding to  
biomolecules)**

**Advanced analytical,  
physical, biochemical  
methods/facilities**


**Basal  
cytotoxicity/other  
molecular end  
points**

**Genotoxic/carcino-  
genic potential**

**Cell  
culture/molecular  
biology techniques**



## *In vitro* NAnoTOXicology research (INATOX) project







## ***Metallic nanoparticles at ECVAM***

**(University of Modena and Colorobbia Group suppliers)**

<b>Nanoparticle</b>	<b>Mean size (nm)</b>
<b>Ag<sup>0</sup></b>	<b>20</b>
<b>Au<sup>0</sup></b>	<b>12</b>
<b>Co<sup>0</sup></b>	<b>50-100</b>
<b>CoFe<sub>2</sub>O<sub>4</sub></b>	<b>15</b>
<b>CoAl<sub>2</sub>O<sub>3</sub></b>	<b>15</b>
<b>Cr antimoniate</b>	<b>20</b>
<b>Ni<sup>0</sup></b>	<b>62</b>
<b>Pt<sup>0</sup></b>	<b>5</b>
<b>SiO<sub>2</sub></b>	<b>20-160</b>
<b>TiO<sub>2</sub></b>	<b>3; 20-30; 20-160</b>
<b>TiO<sub>2</sub>(Ag coated)</b>	<b>3</b>
<b>TiO<sub>2</sub>Sb<sub>2</sub>O<sub>3</sub>Cr<sub>2</sub>O<sub>3</sub></b>	<b>15</b>
<b>ZrO<sub>2</sub></b>	<b>2; 5-30</b>




## Co-nano in H<sub>2</sub>O (SEM microphotograph)






## TiO<sub>2</sub>-nano in H<sub>2</sub>O (SEM microphotograph)



## ZrO<sub>2</sub>-nano in H<sub>2</sub>O (SEM microphotograph)








*1st study involving EU, USA & Japan*

## ***In vitro* Cell Transformation Assay**




**Prevalidation  
initiated in 11/2004**






## The beam line for the production of carrier-free radiotracers





## “Radiolabelling” di Co-nano



Co<sub>nano</sub>

Neutron activation

HFR reactor




$^{60}\text{Co}$

$\beta^-$

$\gamma_1$  1332 KeV

$\gamma_2$  1173 KeV

$^{60}\text{Ni}$



$^{60}\text{Co}_{\text{nano}}$  *h<sub>cp</sub>*



## *Uptake of cobalt in BALB/3T3 cells exposed simultaneously to $^{57}\text{Co}_{\text{sol}}$ and $^{60}\text{Co}_{\text{nano}}$ for 4h*

Concentration ( $\mu\text{M}$ ) $^{60}\text{Co}_{\text{nano}}$ and $^{57}\text{Co}^{2+}$	fgCo·cell <sup>-1(a)</sup>	
	$^{60}\text{Co}_{\text{nano}}$	$^{57}\text{Co}^{2+}$
1	120	0.1
5	720	1.0
10	1900	2.2
30	7300	13.3
50	10000	26.8
70	15000	31.1
100	17385	27.4

(a): mean of 3 experiments;  
RSD<11%.

**Conclusion: obvious different accumulation of Co from Co-nano and Co-sol**






*Intracellular distribution of Co in Balb/3T3 cells exposed for 4h to 100 $\mu$ M of  $^{60}\text{Co}$ -nano (% of total homogenate)*

NUCLEI  
**62 $\pm$ 4.7**

CYTOSOL  
**15.6 $\pm$ 3.3**



CELLULAR MEMBRANE  
**8.3 $\pm$ 4.1**



LYSOSOMES + MITOCHONDRIA + MICROSOMES  
**14.1 $\pm$ 3.6**







**SEM pictures of  
Balb/3T3 cells  
exposed to 100 $\mu$ M Co-  
nano prepared by  
Critical Point Dryer  
technique**






# SEM of Balb/3T3 cells, 100 $\mu$ M Co<sub>nano</sub>







## *Cytotoxicity induced by Co-sol and Co-nano in Balb/3T3 cell line at 4h exposure*



IC<sub>50</sub>

Co<sub>sol</sub>  
41 μM

Co<sub>nano</sub>  
9 μM

**Conclusion: quantitative difference of the induced cytotoxic effect**



## *In Vitro* nanotoxicology research on manufactured nanoparticles

### The future ...

- Full integration of alternative (non animal) methods into “An Integrated and Responsible Approach” concerning a R&D European Strategy for Nanotechnology.
- Creation of a Key Area at ECVAM



## ***Acknowledgements***

**Marlies Halder**

**Enrico Sabbioni**

**Salvador Fortaner**

**Massimo Farina**

**Riccardo Del Torchio**

**Stefano Bosisio**

**Jessica Ponti**

**Barbara Munaro**

**Susan Salovaara**

**François Rossi**

**Takao Sasaki**

**External partners**

**Taskforce Biologicals**

**Antonietta Gatti**

**James Kirkpatrick**

**Lucia Migliore**

**Mario Di Gioacchino**

**Paolo Boscolo**

**Ricard Marcos**

**Giorgio Tettamanti**

**Colorobbia srl**